Quantum Genomics SA (ALQGC):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Quantum Genomics SA (ALQGC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7587
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:50
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥34,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥68,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥102,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Quantum Genomics SA (Quantum Genomics) is a biopharmaceutical company which develops novel medicines in the field of cardiovascular diseases. The company develops drugs to treat high blood pressure and heart failure. Its research programs are based on the Brain Aminopeptidase A Inhibition (BAPAI), a real triple action innovative therapeutic platform. Quantum Genomics BAPAI products pipeline include QGC001 for the treatment of high blood pressure with monotherapy drug; and QGC011 for the treatment of hypertension through combination therapy in pre-clinical phase. The company offers QGC006 for the optimization of the treatment of hypertension with a monotherapy drug; and QGC101 for the prevention and treatment of heart failure. The company partners with biotech research entities, academic teams, and pharmaceutical and bio-science companies to develop new drugs. QGS is headquartered in Paris, France.

Quantum Genomics SA (ALQGC) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Quantum Genomics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Quantum Genomics SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Quantum Genomics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Quantum Genomics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Quantum Genomics SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Quantum Genomics SA, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Quantum Genomics Enters into Research Agreement with University of Ottawa Heart Institute and Center for Interdisciplinary Research in Biology 11
Quantum Genomics Enters into Co-Development Agreement for QGC101 12
Equity Offering 13
Quantum Genomics to Raise USD7.4 Million in First Tranche of Private Placement of Shares 13
Quantum Genomics Raises USD9.6 Million in Private Placement of Shares 14
Quantum Genomics Raises USD3.4 Million in Public Offering of Shares 15
Quantum Genomics Raises USD6 Million in Private Placement of Shares 16
Quantum Genomics Completes Underwriters Exercise of Over-Allotment Option of IPO for USD14.4 Million 17
Quantum Genomics Raises Additional USD0.33 Million in Private Placement of Shares 19
Quantum Genomics Raises USD4.7 Million in Private Placement of Shares 20
Debt Offering 21
Quantum Genomics Raises USD3.7 Million in Public Offering of Bonds 21
Quantum Genomics SA – Key Competitors 22
Quantum Genomics SA – Key Employees 23
Quantum Genomics SA – Locations And Subsidiaries 24
Head Office 24
Recent Developments 25
Strategy And Business Planning 25
Apr 19, 2018: Quantum Genomics enters a new phase of maturity with its BAPAIs Fast Growth strategic plan 25
Financial Announcements 28
Mar 29, 2018: Quantum Genomics publishes its financial results for the year 2017 28
Oct 03, 2017: Quantum Genomics Releases 2017 First-Half Financial Results and First Nine Months Business Update 30
Mar 30, 2017: Quantum Genomics: 2016 annual financial results 32
Corporate Communications 34
Apr 09, 2018: Quantum Genomics strengthens its governance 34
Feb 05, 2018: Quantum Genomics strengthens its Scientific Advisory Board with the appointment of Professor Frans Leenen, a renowned expert in congestive heart failure 35
Jul 11, 2017: Quantum Genomics begins trading in the U.S. on OTCQX 36
Jun 30, 2017: Quantum Genomics appoints Professor Toshiro Fujita as member of its Scientific Advisory Board 37
Apr 25, 2017: Quantum Genomics appoints Bruno Besse as Chief Medical Officer 38
Product News 39
10/27/2017: Quantum Genomics receives the Galien MedStartUp award for the innovative design of its NEW-HOPE study 39
10/16/2017: Quantum Genomics nominated for the Galien MedStartUp Award for the innovative design of its NEW-HOPE trial 40
06/04/2018: FIRIBASTAT Approved as Common International Name for QGC001 by World Health Organization 41
Clinical Trials 42
Nov 15, 2017: Quantum Genomics announces recruitment of first patients in the NEW-HOPE arterial hypertension study in the United States 42
Sep 05, 2017: Quantum Genomics Receives FDA Clearance of IND Application for QGC001 43
Jun 28, 2017: Quantum Genomics announces the design of its next Phase II trial in arterial hypertension, NEW-HOPE 44
Jun 19, 2017: Quantum Genomics details positive results from its Phase IIa trial of QGC001 for the treatment of arterial hypertension 46
May 09, 2017: Quantum Genomics will organize a teleconference on June 19, 2017, to comment on phase IIa data in high blood pressure 48
Mar 14, 2017: Quantum Genomics announces positive data from new preclinical studies with QGC001 49
Appendix 50
Methodology 50
About GlobalData 50
Contact Us 50
Disclaimer 50

List of Tables
Quantum Genomics SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Quantum Genomics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Quantum Genomics SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Quantum Genomics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Quantum Genomics SA, Deals By Therapy Area, 2012 to YTD 2018 9
Quantum Genomics SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Quantum Genomics Enters into Research Agreement with University of Ottawa Heart Institute and Center for Interdisciplinary Research in Biology 11
Quantum Genomics Enters into Co-Development Agreement for QGC101 12
Quantum Genomics to Raise USD7.4 Million in First Tranche of Private Placement of Shares 13
Quantum Genomics Raises USD9.6 Million in Private Placement of Shares 14
Quantum Genomics Raises USD3.4 Million in Public Offering of Shares 15
Quantum Genomics Raises USD6 Million in Private Placement of Shares 16
Quantum Genomics Completes Underwriters Exercise of Over-Allotment Option of IPO for USD14.4 Million 17
Quantum Genomics Raises Additional USD0.33 Million in Private Placement of Shares 19
Quantum Genomics Raises USD4.7 Million in Private Placement of Shares 20
Quantum Genomics Raises USD3.7 Million in Public Offering of Bonds 21
Quantum Genomics SA, Key Competitors 22
Quantum Genomics SA, Key Employees 23

List of Figures
Quantum Genomics SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Quantum Genomics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Quantum Genomics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Quantum Genomics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Quantum Genomics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Quantum Genomics SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Quantum Genomics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Quantum Genomics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Quantum Genomics SA (ALQGC):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Sime Darby Berhad:戦略・SWOT・企業財務分析
    Sime Darby Berhad - Strategy, SWOT and Corporate Finance Report Summary Sime Darby Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Congenica Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Congenica Ltd (Congenica) is a biotechnology company that offers clinical decision support software and services. The company provides research and experimental development on biotechnology. Its technology SAPIENTIA is used to personalize patient care through accurate diagnoses, drug develop …
  • B.O.S. Better OnLine Solutions Ltd (BOSC):企業の財務・戦略的SWOT分析
    Summary B.O.S. Better OnLine Solutions Ltd (B.O.S) is a technology company that offers RFID and supply chain solutions. The company provides RFID and mobile solutions such as automatic identification data capture (AIDC) and radio frequency identification (RFID) hardware, mobile solutions, software a …
  • Applied DNA Sciences Inc (APDN):医療機器:M&Aディール及び事業提携情報
    Summary Applied DNA Sciences Inc (APDN) is a biotechnology company that provides DNA based security and authentication solutions and services. The company’s products comprise DNA security tools, DNA marking kit for assets and valuables, test kits, intruder and offender tagging systems; custom DNA se …
  • Pegasi Energy Resources Corp:石油・ガス:M&Aディール及び事業提携情報
    Summary Pegasi Energy Resources Corp (PERC) is an energy company that explores, produces, and develops oil and natural gas from its properties. The company produces natural gas and oil through the development of a low geological, repeatable, and high potential project in the Rodessa East Texas oil a …
  • Sutro Biopharma Inc (STRO):製薬・医療:M&Aディール及び事業提携情報
    Summary Sutro Biopharma Inc (Sutro Biopharma), formerly Fundamental Applied Biology Inc, discovers, develops and manufactures novel cancer medicines which include antibody-drug conjugates (ADC’s), bispecific antibodies, and antibody-based therapeutics targeting immuno-oncology pathways. Its pipeline …
  • Premera Blue Cross:企業の戦略的SWOT分析
    Premera Blue Cross - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Aero Components Inc.:企業の戦略・SWOT・財務情報
    Aero Components Inc. - Strategy, SWOT and Corporate Finance Report Summary Aero Components Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • El Al Israel Airlines Ltd.:戦略・SWOT・企業財務分析
    El Al Israel Airlines Ltd. - Strategy, SWOT and Corporate Finance Report Summary El Al Israel Airlines Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Linn Energy, LLC:企業の戦略・SWOT・財務情報
    Linn Energy, LLC - Strategy, SWOT and Corporate Finance Report Summary Linn Energy, LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Alethia Biotherapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary Alethia Biotherapeutics Inc (Alethia Biotherapeutics) is a biotechnology company that discovers and develops therapeutic products. The company’s products comprise AB-25E9 bone antiresorptive, AB-3A4 invasive carcinomas treatment products, and AB-16B5 EMT inhibitors. It also offers therapeuti …
  • ANSYS Inc (ANSS):企業の財務・戦略的SWOT分析
    ANSYS Inc (ANSS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Reinsurance Group of America, Incorporated:戦略・SWOT・企業財務分析
    Reinsurance Group of America, Incorporated - Strategy, SWOT and Corporate Finance Report Summary Reinsurance Group of America, Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, …
  • Tata Advanced Systems Ltd:企業の戦略・SWOT・財務情報
    Tata Advanced Systems Ltd - Strategy, SWOT and Corporate Finance Report Summary Tata Advanced Systems Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • International Speedway Corporation:企業の戦略・SWOT・財務分析
    International Speedway Corporation - Strategy, SWOT and Corporate Finance Report Summary International Speedway Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Daybreak Oil and Gas Inc (DBRM):企業の財務・戦略的SWOT分析
    Summary Daybreak Oil and Gas Inc (Daybreak) is an oil and gas company that explores and develops oil and natural gas assets. The company’s projects include East Slopes project and Michigan Basin project. Its East Slopes project is located in south-eastern art of the San Joaquin Basin, California. Da …
  • Adgero Biopharmaceuticals Holdings Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Adgero Biopharmaceuticals Holdings Inc (Adgero), formerly Adgero Biopharmaceuticals Inc is a biopharmaceutical company that develops proprietary late stage photodynamic therapy platform for the treatment of oncology indications. The company’s pipeline products include REM-001. Its product is …
  • Relief Therapeutics Holding AG (RLF):企業の財務・戦略的SWOT分析
    Summary Relief Therapeutics Holding AG (Relief Therapeutics) is a drug development company that offers clinical development of peptides and proteins of natural or engineered origin. The company’s pipeline drug candidates include aviptadil for the treatment of sarcoidosis and low dose interleukin-6 t …
  • Systematic A/S:企業の戦略・SWOT・財務情報
    Systematic A/S - Strategy, SWOT and Corporate Finance Report Summary Systematic A/S - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Compass Health Brands Corp:医療機器:M&Aディール及び事業提携情報
    Summary Compass Health Brands Corp (Compass Health) is a holding company. The company, through its subsidiaries, manufactures and markets medical equipment and devices. It offers bath safety, personal care, durable medical equipment, support surfaces, pressure prevention, mobility, pain management, …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆